Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061256 · ClinicalTrials.gov registry record · Phase 2
The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00061256 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 80 participants.
The verdict
NCT00061256, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
Alendronate is a drug that is used to treat osteoporosis. The purpose of this study is to examine whether alendronate in combination with calcium and vitamin D is safe and effective for treating bone loss in people with HIV.
Interventions
- DRUG Alendronate
- DRUG Vitamin D
- DRUG Calcium carbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061256
The ClinicalTrials.gov registry entry for NCT00061256 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Alendronate is the first listed.
NCT00061256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00061256 about?
NCT00061256 is a clinical study titled "The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients". Alendronate is a drug that is used to treat osteoporosis. The purpose of this study is to examine whether alendronate in combination with calcium and vitamin D is safe and effective for treating bone loss in people with HIV.
What is the current status of trial NCT00061256?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00061256?
The interventions under investigation include: Alendronate (DRUG), Vitamin D (DRUG), Calcium carbonate (DRUG).
Who is sponsoring clinical trial NCT00061256?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.